VWF has also been proposed as a biomarker that has a predictive value for an early three-month response in recurrent glioma to bevacizumab treatment, a neutralizing monoclonal antibody against a vascular endothelial growth factor ligand [156]. This evidence concerns the gene VWF and central nervous system cancer.